Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.45)
# 1,166
Out of 4,835 analysts
327
Total ratings
44.7%
Success rate
11.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Reiterated: Buy | $22 | $11.42 | +92.64% | 17 | Sep 10, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 | $6.04 | +32.45% | 37 | Sep 8, 2026 | |
| UPB Upstream Bio | Reiterated: Buy | $36 | $5.70 | +531.58% | 3 | Sep 2, 2026 | |
| ALDX Aldeyra Therapeutics | Reiterated: Hold | $2 | $1.34 | +49.25% | 32 | Aug 17, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $58 | $32.89 | +76.35% | 16 | Aug 17, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $36 | $13.17 | +173.35% | 34 | Aug 14, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $31.34 | +40.40% | 16 | Aug 14, 2026 | |
| LENZ LENZ Therapeutics | Reiterated: Buy | $38 | $4.52 | +740.71% | 18 | Aug 12, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $29.34 | +90.87% | 20 | Aug 12, 2026 | |
| DMAC DiaMedica Therapeutics | Reiterated: Buy | $12 | $6.45 | +86.05% | 13 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $19.41 | +126.75% | 10 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.58 | +402.79% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $80.71 | +9.03% | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.9517 | +530.45% | 13 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $6 | $1.61 | +272.67% | 13 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $8.36 | +211.00% | 21 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.023 | n/a | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.49 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $8.53 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $70.06 | n/a | 5 | Oct 21, 2022 |
Immunic
Sep 10, 2026
Reiterated: Buy
Price Target: $22
Current: $11.42
Upside: +92.64%
Opus Genetics
Sep 8, 2026
Reiterated: Buy
Price Target: $8
Current: $6.04
Upside: +32.45%
Upstream Bio
Sep 2, 2026
Reiterated: Buy
Price Target: $36
Current: $5.70
Upside: +531.58%
Aldeyra Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: $2
Current: $1.34
Upside: +49.25%
Kodiak Sciences
Aug 17, 2026
Reiterated: Buy
Price Target: $58
Current: $32.89
Upside: +76.35%
4D Molecular Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $36
Current: $13.17
Upside: +173.35%
Zenas BioPharma
Aug 14, 2026
Reiterated: Buy
Price Target: $44
Current: $31.34
Upside: +40.40%
LENZ Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $38
Current: $4.52
Upside: +740.71%
Mineralys Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $56
Current: $29.34
Upside: +90.87%
DiaMedica Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $12
Current: $6.45
Upside: +86.05%
Aug 10, 2026
Reiterated: Buy
Price Target: $44
Current: $19.41
Upside: +126.75%
Aug 7, 2026
Reiterated: Buy
Price Target: $18
Current: $3.58
Upside: +402.79%
Aug 7, 2026
Reiterated: Buy
Price Target: $88
Current: $80.71
Upside: +9.03%
Aug 6, 2026
Reiterated: Buy
Price Target: $6
Current: $0.9517
Upside: +530.45%
Aug 4, 2026
Reiterated: Buy
Price Target: $8 → $6
Current: $1.61
Upside: +272.67%
Jul 31, 2026
Reiterated: Buy
Price Target: $26
Current: $8.36
Upside: +211.00%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.023
Upside: n/a
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $3.49
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Reiterated: Buy
Price Target: $39
Current: $8.53
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $70.06
Upside: n/a